Prescient Therapeutics Limited (ASX:PTX)

Australia flag Australia · Delayed Price · Currency is AUD
0.0460
-0.0010 (-2.13%)
Aug 1, 2025, 3:59 PM AEST
-2.13%
Market Cap45.09M
Revenue (ttm)3.02M
Net Income (ttm)-7.07M
Shares Out980.32M
EPS (ttm)-0.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,517,468
Average Volume1,449,996
Open0.0470
Previous Close0.0470
Day's Range0.0460 - 0.0480
52-Week Range0.0370 - 0.0630
Beta0.51
RSI55.42
Earnings DateAug 22, 2025

About United States Steel

Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-100, a first in class compound with the ability to block an cancer growth enzyme, thereby disrupting the oncogenic Ras pathway. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1986
Employees 3
Stock Exchange Australian Securities Exchange
Ticker Symbol PTX
Full Company Profile

Financial Performance

In 2024, Prescient Therapeutics's revenue was 3.71 million, an increase of 52.89% compared to the previous year's 2.43 million. Losses were -8.24 million, 17.6% more than in 2023.

Financial Statements

News

There is no news available yet.